

**Editor**

Tore K Kvien

Associate Editors

Francis Berenbaum
Johannes Bijlsma
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes
David Pisetsky

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 12.384

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2017 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431 POSTMASTER: send address changes to Annals of the Rheumatic Diseases, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

Editorial

- 779** Lesinurad combination therapy with allopurinol in gout: do CLEAR studies make the treatment of gout clearer?
J A Singh

Criteria

- 782** 2016 American College of Rheumatology/ European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/ Paediatric Rheumatology International Trials Organisation Collaborative Initiative
L G Rider, R Aggarwal, A Pistorio, N Bayat, B Erman, B M Feldman, A M Huber, R Cimaz, R J Cuttita, S K de Oliveira, C B Lindsley, C A Pilkington, M Punaro, A Ravelli, A M Reed, K Rouster-Stevens, A van Royen-Kerkhof, F Dressler, C Saad Magalhaes, T Constantin, J E Davidson, B Magnusson, R Russo, L Villa, M Rinaldi, H Rockette, P A Lachenbruch, F W Miller, J Vencovsky, N Ruperto, for the International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation

- 792** 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/ Paediatric Rheumatology International Trials Organisation Collaborative Initiative
R Aggarwal, L G Rider, N Ruperto, N Bayat, B Erman, B M Feldman, C V Oddis, A A Amato, H Chinoy, R G Cooper, M Dastmalchi, D Fiorentino, D Isenberg, J D Katz, A Mammen, M de Visser, S R Ytterberg, I E Lundberg, L Chung, K Danko, I Garcia-De la Torre, Y W Song, L Villa, M Rinaldi, H Rockette, P A Lachenbruch, F W Miller, J Vencovsky, for the International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation

Recommendation

- 802** EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures
W F Lems, K E Dreinhöfer, H Bischoff-Ferrari, M Blauth, E Czerwinski, JAP da Silva, A Herrera, P Hoffmeyer, T Kvien, G Maalouf, D Marsh, J Puget, W Puhl, G Poor, L Rasch, C Roux, S Schieler, B Seriola, U Tarantino, T van Geel, A Woolf, C Wyers, P Geusens

Clinical and epidemiological research

- 811** Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)
T Bardin, R T Keenan, P P Khanna, J Kopicko, M Fung, N Bhakta, S Adler, C Storgard, S Baumgartner, A So
- 821** Development of the autoinflammatory disease damage index (ADDI)
N M ter Haar, K V Annink, S M Al-Mayouf, G Amaryan, J Anton, K S Barron, S M Benseler, P A Brogan, L Cantarini, M Cattalini, A-V Cochino, F De Benedetti, F Dedeoglu, A A De Jesus, O Della Casa Alberighi, E Demirkaya, P Dolezalova, K L Durrant, G Fabio, R Gallizzi, R Goldbach-Mansky, E Hachulla, V Hentgen, T Herlin, M Hofer, H M Hoffman, A Insalaco, A F Jansson, T Kallinich, I Koné-Paut, A Kozlova, J B Kuenmerle-Deschner, H J Lachmann, R M Laxer, A Martini, S Nielsen, I Nikishina, A K Ombrello, S Ozen, E Papadopoulou-Alataki, P Quartier, D Rigante, R Russo, A Simon, M Trachana, Y Uziel, A Ravelli, M Gattorno, J Frenkel
- 831** A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate
J S Smolen, S K Agarwal, E Ilivanova, X L Xu, Y Miao, Y Zhuang, I Nnane, W Radziszewski, A Greenspan, A Beutler, D Baker
- 840** Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial
G R Burmester, Y Lin, R Patel, J van Adelsberg, E K Mangan, N M H Graham, H van Hoogstraten, D Bauer, J Ignacio Vargas, E B Lee

MORE CONTENTS ►



This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals Open Access scheme.

See <http://authors.bmj.com/open-access/>

Member since 2008
JMG0004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>

equator
network

recycle
When you have finished
with this please recycle it

- 848** Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis
G Ozen, S Pedro, M E Holmqvist, M Avery, F Wolfe, K Michaud
- 855** The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission
L H D van Tuyl, M Sadlonova, S Hewlett, B Davis, C Flurey, N Goel, L Gossec, C Heegaard Brahe, C L Hill, W Hoogland, J Kirvan, M L Hetland, D van Schaardenburg, J S Smolen, T Stamm, M Voshaar, G A Wells, M Boers
- 862** Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis
OPEN ACCESS
J B Lilleker, A Rietveld, S R Pye, K Mariampillai, O Benveniste, M T J Peeters, J A L Miller, M G Hanna, P M Machado, M J Parton, K R Gheorghe, U A Badrising, I E Lundberg, S Sacconi, M K Herbert, N J McHugh, B R F Lecky, C Brierley, D Hilton-Jones, J A Lamb, M E Roberts, R G Cooper, C G J Saris, G J M Pruijn, H Chinoy, B G M van Engelen, On behalf of all UKMYONET contributors
- 869** GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes
OPEN ACCESS
A Nakayama, H Nakaoka, K Yamamoto, M Sakiyama, A Shaukat, Y Toyoda, Y Okada, Y Kamatani, T Nakamura, T Takada, K Inoue, T Yasujima, H Yuasa, Y Shirahama, H Nakashima, S Shimizu, T Higashino, Y Kawamura, H Ogata, M Kawaguchi, Y Ohkawa, I Danjoh, A Tokumasu, K Ooyama, T Ito, T Kondo, K Wakai, B Stiburkova, K Pavelka, L K Stamp, N Dalbeth, Eurogout Consortium, Y Sakurai, H Suzuki, M Hosoyamada, S Fujimori, T Yokoo, T Hosoya, I Inoue, A Takahashi, M Kubo, H Ooyama, T Shimizu, K Ichida, N Shinomiya, T R Merriman, H Matsuo
- 878** An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series
G Varkas, K Thevissen, G De Brabanter, L Van Praet, F Czul-gurdian, H Cypers, J De Kock, P Carron, M De Vos, P Hindryckx, J Arts, I Vanneuville, P Schoenaers, B Claerhout, M Abreu, F Van den Bosch, D Elewaut
- 882** The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study
A Ogdie, L Harter, D Shin, J Baker, J Takeshita, H K Choi, T J Love, J M Gelfand
- 886** Performance of the ASAS classification criteria for axial and peripheral spondyloarthritis: a systematic literature review and meta-analysis
A Sepriano, R Rubio, S Ramiro, R Landewé, D van der Heijde
- Basic and translational research**
- 891** Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase
N Müller-Calleja, D Mantukyan, A Canisius, D Strand, K J Lackner
- 898** An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy
C Miyabe, Y Miyabe, K Strle, N D Kim, J H Stone, A D Luster, S Unizony
- 906** Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications
OPEN ACCESS
M J Ombrello, V L Arthur, E F Remmers, A Hinks, I Tachmazidou, A A Grom, D Foell, A Martini, M Gattorno, S Özen, S Prahalad, A S Zeff, J F Bohnsack, N T Ilowite, E D Mellins, R Russo, C Len, M Odete E Hilario, S Oliveira, R S M Yeung, A M Rosenberg, L R Wedderburn, J Anton, J-P Haas, A Rosen-Wolff, K Minden, K Tenbrock, E Demirkaya, J Cobb, E Baskin, S Signa, E Shuldiner, R H Duerr, J-P Achkar, M I Kamboh, K M Kaufman, L C Kottyan, D Pinto, S W Scherer, M E Alarcón-Riquelme, E Docampo, X Estivill, A Gül, British Society of Pediatric and Adolescent Rheumatology (BSPAR) Study Group, Inception Cohort of Newly Diagnosed Patients with Juvenile Idiopathic Arthritis (ICON-JIA) Study Group, Childhood Arthritis Prospective Study (CAPS) Group, Randomized Placebo Phase Study of Rilonacept in sJIA (RAPPORT) Investigators, Sparks-Childhood Arthritis Response to Medication Study (CHARMS) Group, Biologically Based Outcome Predictors in JIA (BBOP) Group, C D Langefeld, S Thompson, E Zeggini, D L Kastner, P Woo, W Thomson
- 914** CCL2/CCR2, but not CCL5/CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in osteoarthritis
H Raghu, C M Lepus, Q Wang, H H Wong, N Lingampalli, F Oliviero, L Punzi, N J Giori, S B Goodman, C R Chu, J B Sokolove, W H Robinson
- 924** Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis
M Manetti, E Romano, I Rosa, S Guiducci, S Bellando-Randone, A De Paulis, L Ibba-Manneschi, M Matucci-Cerinic
- Electronic pages**
- Correspondence**
- e9** Criteria for CAPS, is it all in the name?
I Touitou, G Sarrabay
- e10** Response to: 'Criteria for CAPS, is it all in the name?' by Touitou and Sarrabay
J B Kuemmerle-Deschner, S M Benseler
- e11** PP2A plays a key role in inflammation and cancer through tristetraprolin activation
I Cristóbal, B Torrejón, J Madoz-Gúrpide, F Rojo, J García-Foncillas